Longeveron Inc.

1.45
-0.11 (-7.05%)
At close: Apr 03, 2025, 3:59 PM
1.47
1.85%
Pre-market: Apr 04, 2025, 07:02 AM EDT

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.

The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.
Longeveron Inc. logo
Country United States
IPO Date Feb 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 25
CEO Mohamed Wa'el Ahmed Hashad M.B.A.

Contact Details

Address:
1951 NW 7th Avenue
Miami, Florida
United States
Website https://www.longeveron.com

Stock Details

Ticker Symbol LGVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001721484
CUSIP Number 54303L104
ISIN Number US54303L1044
Employer ID 47-2174146
SIC Code 2834

Key Executives

Name Position
Mohamed Wa'el Ahmed Hashad M.B.A. Chief Executive Officer & Director
Devin Blass Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls
Lisa A. Locklear M.B.A. Chief Financial Officer, Executive Vice President & Treasurer
Brian G Rash Ph.D. Vice President of Research & Discovery
Dr. Joshua Michael Hare FACC, M.D. Co-Founder, Chief Science Officer & Chairman
Dr. Nataliya Agafonova M.D. Chief Medical Officer
Heather Zhou Vice President & Corporate Controller
Lisa McClain-Moss Vice President of Manufacturing
Paul T. Lehr J.D. General Counsel & Secretary

Latest SEC Filings

Date Type Title
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Mar 28, 2025 S-3 Filing
Mar 14, 2025 8-K Current Report
Mar 06, 2025 4 Filing
Feb 28, 2025 8-K Current Report
Feb 28, 2025 10-K Annual Report
Jan 30, 2025 8-K Current Report